Pharma reputation drops to pre-pandemic normal, with Pfizer and Moderna falling in the ranks

Public perception of pharma companies has dropped since peaking during the COVID-19 pandemic, according to a recent study released by Caliber, a corporate reputation monitoring and management platform.

After experiencing a surge in reputation over the past few years, the view of Big Pharma in the public eye may have returned to a ‘new normal’ as the pandemic fades into endemicity.